Insider · CIK 0001609879
Jeffrey S. Hatfield
Files at VIR (Vir Biotechnology, Inc.). First filing -, latest -.
Jeffrey S. Hatfield files SEC Form 4 as director at VIR (Vir Biotechnology, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey S. Hatfield has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | VIR Vir Biotechnology, Inc. | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 39,806 | May 28, 2026 |
| May 27, 2026 | VIR Vir Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | May 28, 2026 |
| May 30, 2025 | VIR Vir Biotechnology, Inc. | AGrant or award Common Stock | +8,000 | $0.00 | $0 | 31,806 | Jun 2, 2025 |
| May 30, 2025 | VIR Vir Biotechnology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 2, 2025 |
Questions about Jeffrey S. Hatfield
Answered from the filings on this page, as of the latest one.
Is Jeffrey S. Hatfield buying or selling?
Jeffrey S. Hatfield has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey S. Hatfield's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey S. Hatfield has 0.
Where does Jeffrey S. Hatfield file Form 4?
Jeffrey S. Hatfield has filed Form 4 at VIR (Vir Biotechnology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.